C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/4025 (2006.01) A61K 31/4375 (2006.01) A61K 31/4545 (2006.01) A61K 31/495 (2006.01) C07D 211/14 (2006.01) C07D 295/182 (2006.01) C07D 309/04 (2006.01) C07D 309/14 (2006.01)
Patent
CA 2697580
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.
L'invention concerne de nouveaux composés de formule (I), des sels pharmaceutiquement acceptables de ceux-ci, des promédicaments de ceux-ci, des métabolites biologiquement actifs de ceux-ci, des isomères de ceux-ci ou des stéréo-isomères de ceux-ci, les variables étant définies selon l'invention. Les composés de formule (I) sont utiles en tant qu'antagonistes d'un récepteur de chimiokine et seraient utiles en tant que tels dans le traitement de certains états et maladies, en particulier des états et maladies inflammatoires et des troubles prolifératifs et des états, par exemple, d'arthrite rhumatoïde, d'ostéoarthrite, de scléroses multiples et d'asthme.
Ansell Graham K.
Ericsson Anna M.
George Dawn M.
Li Biqin
Wang Lu
Abbott Laboratories
Torys Llp
LandOfFree
Octahydropentalene compounds as chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Octahydropentalene compounds as chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydropentalene compounds as chemokine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1782191